Patient characteristics and outcomes
| Characteristic . | Incidence, n (%) . |
|---|---|
| Age,y | |
| 0 > age < 1 | 22 (12) |
| 1 ≥ age < 5 | 49 (27) |
| 5 ≥ age < 13 | 58 (32) |
| 13 ≥ age < 20 | 52 (29) |
| Sex | |
| Male | 104 (57) |
| Female | 77 (43) |
| Race* | |
| Northern European | 130 (72) |
| African/North African | 13 (7) |
| Multiracial/other | 12 (7) |
| Asian/Southeast Asian | 10 (5.5) |
| Middle Eastern/Persian/Turkish | 10 (5.5) |
| Eastern European/Russian | 6 (3) |
| HCT years | |
| 2005-2008 | 22 (12) |
| 2009-2012 | 66 (37) |
| 2013-2016 | 93 (51) |
| HCT indication | |
| Malignancy | 90 (50) |
| Primary immunodeficiency | 37 (20) |
| Metabolic/inborn error of metabolism | 29 (16) |
| Bone marrow failure syndrome | 21 (12) |
| Autoimmune disease | 4 (2) |
| Allograft donor† | |
| Mismatched UCB | 72 (40) |
| Matched UCB | 45 (25) |
| Matched sibling donor | 37 (20) |
| Matched unrelated donor | 27 (15) |
| Conditioning‡ | |
| Myeloablative | 172 (95) |
| Reduced intensity | 9 (5) |
| Serotherapy | |
| ATG or alemtuzumab | 125 (69) |
| BALF routine microbiology§ | |
| Any abnormality | 90 (50) |
| Virus detected on PCR | 54 (30) |
| Bacterial culture growth | 31 (17) |
| Fungal culture growth | 22 (12) |
| GM positivity | 21 (13) |
| Post-HCT lung injury | |
| Yes | 39 (22) |
| Infection | 13 (7) |
| IPS or unknown | 16 (9) |
| Bronchiolitis obliterans | 10 (6) |
| No | 142 (78) |
| Post-HCT mortality | |
| NRM | 39 (21) |
| Due to lung injury | 17 (9) |
| Not due to lung injury | 22 (12) |
| Relapse mortality | 12 (7) |
| Overall survival | 130 (72) |
| Characteristic . | Incidence, n (%) . |
|---|---|
| Age,y | |
| 0 > age < 1 | 22 (12) |
| 1 ≥ age < 5 | 49 (27) |
| 5 ≥ age < 13 | 58 (32) |
| 13 ≥ age < 20 | 52 (29) |
| Sex | |
| Male | 104 (57) |
| Female | 77 (43) |
| Race* | |
| Northern European | 130 (72) |
| African/North African | 13 (7) |
| Multiracial/other | 12 (7) |
| Asian/Southeast Asian | 10 (5.5) |
| Middle Eastern/Persian/Turkish | 10 (5.5) |
| Eastern European/Russian | 6 (3) |
| HCT years | |
| 2005-2008 | 22 (12) |
| 2009-2012 | 66 (37) |
| 2013-2016 | 93 (51) |
| HCT indication | |
| Malignancy | 90 (50) |
| Primary immunodeficiency | 37 (20) |
| Metabolic/inborn error of metabolism | 29 (16) |
| Bone marrow failure syndrome | 21 (12) |
| Autoimmune disease | 4 (2) |
| Allograft donor† | |
| Mismatched UCB | 72 (40) |
| Matched UCB | 45 (25) |
| Matched sibling donor | 37 (20) |
| Matched unrelated donor | 27 (15) |
| Conditioning‡ | |
| Myeloablative | 172 (95) |
| Reduced intensity | 9 (5) |
| Serotherapy | |
| ATG or alemtuzumab | 125 (69) |
| BALF routine microbiology§ | |
| Any abnormality | 90 (50) |
| Virus detected on PCR | 54 (30) |
| Bacterial culture growth | 31 (17) |
| Fungal culture growth | 22 (12) |
| GM positivity | 21 (13) |
| Post-HCT lung injury | |
| Yes | 39 (22) |
| Infection | 13 (7) |
| IPS or unknown | 16 (9) |
| Bronchiolitis obliterans | 10 (6) |
| No | 142 (78) |
| Post-HCT mortality | |
| NRM | 39 (21) |
| Due to lung injury | 17 (9) |
| Not due to lung injury | 22 (12) |
| Relapse mortality | 12 (7) |
| Overall survival | 130 (72) |
ATG, antithymocyte globulin; IPS, idiopathic pneumonia syndrome; UCB, umbilical cord blood.
Includes 1 Hispanic patient and 1 patient from Suriname.
The majority of non–UCB grafts were obtained from bone marrow (n = 62); only 2 were from peripheral blood. Includes 1 8/10 mismatched sibling donor and 1 9/10 mismatched unrelated donor. The majority of cytomegalovirus serostatuses were unknown/assumed positive because of the use of UCB.
Most myeloablative conditioning was busulfan/fludarabine (n = 82), busulfan/fludarabine/clofarabine (n = 47), or total body irradiation/etoposide (n = 13). The majority of reduced-intensity conditioning was fludarabine based.
No organisms were detected with other diagnostic tests, such as cytology for Pneumocystis carinii pneumonia or PCR for Mycoplasma or Legionella. Some patients had >1 abnormality.